Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome

References

• Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977;37:635–42.
   PubMed Web of Science ®Google Scholar
• Henriksen JH. Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. J Hepatol 1995;23:25– 30.
   Google Scholar
• Bernardi M, Blendis L, Burroughs AK, Laffi G, Rodés J, Gentilini P. Hepatorenal syndrome and ascites: questions and answers. Liver 1999;19:15–74.
   Google Scholar
• Dagher L, Moore K. The hepatorenal syndrome. Gut 2001;49:729–37.
   PubMed Web of Science ®Google Scholar
• Gentilini P, Vizzutti F, Gentilini A, Zipoli M, Foschi M, Romanelli RG. Update on ascites and hepatorenal syndrome. Dig Liver Dis 2002;34:592–605.
   PubMedGoogle Scholar
• Gines P, Cardenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646–54.
   PubMed Web of Science ®Google Scholar
• Gines P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003;362:1819–27.
   PubMed Web of Science ®Google Scholar
• Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164–76.
   PubMed Web of Science ®Google Scholar
• Epstein M. Renal sodium handling in liver disease. In: Epstein M, editor. The kidney in lLiver disease, 4th ed. Philadelphia: Hanley and Belfus; 1996. pp 1–31.
   Google Scholar
• Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151–7.
   Google Scholar
• Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997;17:505–19.
   PubMed Web of Science ®Google Scholar
• Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478–91.
   PubMed Web of Science ®Google Scholar
• La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34:19–27.
   Google Scholar
• Gerbes AL, Gülberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998;28: 683–8.
   PubMed Web of Science ®Google Scholar
• Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50:90–4.
   Google Scholar
• Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839–47.
   Google Scholar
• Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Sem Liver Dis 1994; 14:71–81.
   PubMed Web of Science ®Google Scholar
• Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment. Gastroenterology 2002;122:1658–76.
   Google Scholar
• Cassinello C, Moreno E, Gozalo A, Ortuno B, Cuenca B, Solis-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003;48:179–86.
   Google Scholar
• Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S69–89.
   PubMed Web of Science ®Google Scholar
• Kostreva DR, Pontus SP. Hepatic vein, hepatic parenchymal, and inferior vena caval mechanoreceptors with phrenic afferents. Am J Physiol 1993;28:G15–20.
   Google Scholar
• Levy M, Wexler MJ. Hepatic denervation alters first-phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol 1987;253:F664–F71.
   Google Scholar
• Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997;40:664–70.
   Google Scholar
• Kapoor D, Redhead DN, Hayes PC, Webb DJ, Jalan R. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003;9:32–9.
   Google Scholar
• Ming Z, Smyth DD, Lautt WW. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine. Hepatology 2002;35:167–75.
   Google Scholar
• Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Arroyo V, Gines P, Rodés J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. Malden: Blackwell; 1999. pp 307–29.
   Google Scholar
• Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment, 1st ed. Oxford: Blackwell; 1994. pp 17–26.
   Google Scholar
• Møller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998;58: 361–72.
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Ring-Larsen H. Hepatorenal disorders:Role of the sympathetic nervous system. Sem Liver Dis 1994; 14:35–43.
   PubMed Web of Science ®Google Scholar
• Jalan R, Mookerjee RP, Hayes PC, Redhead DN, Moore K, Williams R. Evidence for altered renal blood flow auto-reulation in cirrhosis. Hepatology 2003;38:416A–7A.
   Google Scholar
• Dagher L, Patch D, Marley R, Moore K, Burroughs A. Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients [review]. [in process citation]. Aliment Pharmacol Ther 2000;14:515–21.
   PubMed Web of Science ®Google Scholar
• Llach J, Ginés P, Arroyo V, Rimola A, Titó L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482–7.
   PubMed Web of Science ®Google Scholar
• Thiesson HC, Skøtt O, Jespersen B, Schaffalitzky de Muckadell OB. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites. Am J Gastroenterol 2003;98:180–6.
   Google Scholar
• Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451–9.
   PubMed Web of Science ®Google Scholar
• Ruiz-Del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210–8.
   PubMed Web of Science ®Google Scholar
• La Villa G, Salmeron JM, Arroyo V, Bosch J, Gines P, Garcia-Pagan JC, et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992;102:2114–9.
   Google Scholar
• Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders. Role of the renin-angiotensin-aldosterone system. Sem Liver Dis 1994;14:23–34.
   Google Scholar
• Møller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001;61:421–9.
   PubMed Web of Science ®Google Scholar
• Dibona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75–197.
   PubMed Web of Science ®Google Scholar
• Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993;104:588–94.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Abraldes J, Albillos A, Banares R, del Arbol LR, Moitinho E, Rodriguez C, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382–8.
   PubMed Web of Science ®Google Scholar
• Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37:182–91.
   PubMed Web of Science ®Google Scholar
• Gerbes AL, Gülberg V, Gines P, Decaux G, Gross P, Gandjini H, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124: 933–9.
   PubMed Web of Science ®Google Scholar
• Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993;17:355–60.
   Google Scholar
• Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416–22.
   PubMed Web of Science ®Google Scholar
• Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288–95.
   PubMed Web of Science ®Google Scholar
• Colombato LA, Spahr L, Martinet JP, Dufresne MP, Lafortune M, Fenyves D, et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut 1996;39:600–4.
   PubMed Web of Science ®Google Scholar
• Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002;97:142–8.
   PubMed Web of Science ®Google Scholar
• Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, et al. Humoral and cardiac effects of TIPS in cirrhotic patients with different “effective” blood volume. Hepatology 2003;38:1370–7.
   PubMed Web of Science ®Google Scholar
• Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40: 55–64.
   Google Scholar
• Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993; 18:688–95.
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998;29:328–41.
   PubMed Web of Science ®Google Scholar
• Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999;30:479–84.
   PubMed Web of Science ®Google Scholar
• Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277–86.
   PubMed Web of Science ®Google Scholar
• Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233–43.
   PubMed Web of Science ®Google Scholar
• Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004;10:1099–6.
   Google Scholar
• Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565–70.
   PubMed Web of Science ®Google Scholar
• Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33:43–8.
   PubMed Web of Science ®Google Scholar
• Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20: 51—9.
   PubMedGoogle Scholar
• Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001;64:15–9.
   PubMed Web of Science ®Google Scholar
• Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36:941–8.
   Google Scholar
• Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923–30.
   PubMed Web of Science ®Google Scholar
• Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility ofhepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35–41.
   Google Scholar
• Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, Rehling M, Henriksen JH, Pedersen EB, et al. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial. Hepatology 2001;34:471–7.
   Google Scholar
• Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374–80.
   Google Scholar
• Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238–43.
   Google Scholar
• Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690–7.
   PubMed Web of Science ®Google Scholar
• Dillon JF, Nolan J, Thomas H, Williams BC, Neilson JMM, Bouchier IAD, et al. The correction of autonomic dysfunction in cirrhosis by captopril. J Hepatol 1997;26: 331–5.
   PubMed Web of Science ®Google Scholar
• Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol 2002;97:707–13.
   Google Scholar
• Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol 1994;89:750–7.
   PubMed Web of Science ®Google Scholar
• Laffi G, Barletta G, Lavilla G, Delbene R, Riccardi D, Ticali P, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997;113:891–8.
   PubMed Web of Science ®Google Scholar
• Villa GL, Barletta G, Romanelli RG, Laffi G, Del Bene R, Vizzutti F, et al. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002;35: 1441–8.
   PubMed Web of Science ®Google Scholar
• Moreau R, Hadengue A, Soupison T, Mechin G, Assous M, Roche-Sicot J, et al. Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanisms. Hepatology 1990;12:7–12.
   Google Scholar
• Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993;105:1167–72.
   Google Scholar
• Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9–15.
   Google Scholar
• Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 1995;22:472–8.
   PubMed Web of Science ®Google Scholar
• Bernardi M, Fornale L, Dimarco C, Trevisani F, Baraldini M, Gasbarrini A, et al. Hyperdynamic circulation of advanced cirrhosis: a reappraisal based on posture-induced changes in hemodynamics. J Hepatol 1995;22:309–18.
   PubMed Web of Science ®Google Scholar
• Luca A, Feu F, Garcia-Pagan JC, Jiménez W, Arroyo V, Bosch J, et al. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 1994;20:30–3.
   Google Scholar
• Ruiz del Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579–86.
   PubMed Web of Science ®Google Scholar
• Cabrera J, Falcon L, Gorriz E, Pardo MD, Granados R, Quinones A, et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. Gut 2001;48:384–9.
   PubMed Web of Science ®Google Scholar
• Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147–53.
   PubMed Web of Science ®Google Scholar
• Arroyo V, Jimenez W. Clinical need for antidiuretic hormone antagonists in cirrhosis. Hepatology 2003;37: 13–5.
   PubMed Web of Science ®Google Scholar
• Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774– 8.
   PubMed Web of Science ®Google Scholar
• Anand R, Harry D, Holt S, Milner P, Dashwood M, Goodier D, et al. Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. Gut 2002;50:111–7.
   PubMed Web of Science ®Google Scholar
• Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 1990;11:153–8.
   PubMed Web of Science ®Google Scholar
• Moore K, Ward PS, Taylor GW, Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991;100:1069–77.
   PubMed Web of Science ®Google Scholar
• Epstein M, Schneider N, Befeler B. Relationship of systemic and intrarenal hemodynamics in cirrhosis. J Lab Clin Med 1977;89:1175–87.
   Google Scholar
• Epstein M. Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy. J Am Soc Nephrol 1994;4: 1735–53.
   PubMed Web of Science ®Google Scholar
• Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29:334–9.
   Google Scholar
• Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. Gastroenterology 1999;117:740–2.
   PubMedGoogle Scholar
• Epstein M, Weitzman RE, Preston S, Denunzio AG. Relationship between plasma arginine vasopressin and renal water handling in decompensated cirrhosis. Min Electr Metab 1984;10:155–65.
   PubMedGoogle Scholar
• Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002;36: 1197–205.
   Google Scholar
• FernandezLlama P, Turner R, Dibona G, Knepper MA. Renal expression of aquaporins in liver cirrhosis induced by chronic common bile duct ligation in rats. J Am Soc Nephrol 1999;10:1950–7.
   PubMed Web of Science ®Google Scholar
• Claria J, Jimenez W, Arroyo V, La Villa G, Lopez C, Asbert M, et al. Effect of V-1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991;100: 494–501.
   Google Scholar
• Morales J, Moitinho E, Abraldes JG, Fernandez M, Bosch J. Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. Hepatology 2003;38: 1378–83.
   Google Scholar
• Gerbes AL, Møller S, Gülberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735–9.
   PubMed Web of Science ®Google Scholar
• Møller S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996;56:481–90.
   PubMed Web of Science ®Google Scholar
• Bernardi M, Gülberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL. Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol 1996;24: 161–8.
   PubMed Web of Science ®Google Scholar
• Moore K. Endothelin and vascular function in liver disease. Gut 2004;53:159–61.
   PubMed Web of Science ®Google Scholar
• Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996;347:1842–3.
   Google Scholar
• Llach J, Gines P, Arroyo V, Salmeron JM, Gines A, Jimenez W, et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology 1993;17:59–64.
   PubMed Web of Science ®Google Scholar
• Milani L, Merkel C, Gatta A. Renal effects of aminophylline in hepatic cirrhosis. Eur J Clin Pharmacol 1983;24: 757–60.
   PubMed Web of Science ®Google Scholar
• Forrest EH, Bouchier IAD, Hayes PC. Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis. Gut 1997;40:139–44.
   Google Scholar
• Stanley AJ, Forrest EH, Dabos K, Bouchier IAD, Hayes PC. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites. Gastroenterology 1998;115: 406–11.
   Google Scholar
• Angeli P, Jimenez W, Arroyo V, Mackenzie HS, Zhang PL, Claria J, et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994; 20:948–54.
   PubMed Web of Science ®Google Scholar
• Ros J, Claria J, Jimenez W, Boschmarce M, Angeli P, Arroyo V, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995;22:915–20.
   PubMed Web of Science ®Google Scholar
• Zipser RD, Radvan GM, Kronborg IJ, Duke R, Little T. Urinary thromboxane B2 and prostaglandinE2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983;84: 697–703.
   Google Scholar
• Rimola A, Gines P, Arroyo V. Urinary excretion of 6-keto-PGF-1-alpha, thromboxane B-2 and prostaglandin E-2 in cirrhosis with ascites: relationship to functional renal failure (hepatorenal syndrome). J Hepatol 1986;3: 111–7.
   Google Scholar
• Gines A, Salmeron JM, Gines P, Arroyo V, Jimenez W, Rivera F, et al. Oral misoprostol or intravenous prostaglandin E2 does not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993;17:220–6.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114: 344–51.
   PubMed Web of Science ®Google Scholar
• McNaughton L, Puttagunta L, Martinez-Cuesta MA, Kneteman N, Mayers I, Moqbel R, et al. Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acad Sci USA 2002;99:17161–6.
   PubMed Web of Science ®Google Scholar
• Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver 2001;21:161–74.
   PubMedGoogle Scholar